ABAmanda Black

Amanda Black

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Amanda Black has a total of 88 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Risk of Prostate Cancer–related Death Following a Low PSA Level in the PLCO Trial

    by Rebecca Landy, Lauren C. Houghton, Christine D. Berg, Robert L. Grubb, Hormuzd A. Katki, Amanda Black

    Longer-than-annual screening intervals have been suggested to improve the balance of benefits and harms in prostate cancer screening. Many researchers, societies, and guideline committees have suggested that screening intervals could depend on the prostate-specific antigen (PSA) result. We analyzed data from men (N = 33,897) ages 55–74 years with a baseline PSA test in the intervention arm of the Prostate, Lung, Colorectal and Ovarian Cancer Screening trial (United States, 1993–2001). We estimated 5- and 10-year risks of aggressive cancer (Gleason ≥8 and/or stage III/IV) and 15-year risks of prostate cancer–related mortality for men with baseline PSA ≤ 0.5 ng/mL (N = 4,862), ≤1 ng/mL (N = 15,110), and 1.01–2.5 ng/mL (N = 12,422). A total of 217 men died from prostate cancer through 15 years, although no men with PSA ≤ 1 ng/mL died from prostate cancer within 5 years [95% confidence interval (CI), 0.00%–0.03%]. The 5-year incidence of aggressive disease was low (0.08%; 95% CI, 0.03%–0.12%) for men with PSA ≤ 1 ng/mL, and higher for men with baseline PSA 1.01–2.5 ng/mL (0.51%; 95% CI, 0.38%–0.74%). No men aged ≥65 years with PSA ≤ 0.5 ng/mL died from prostate cancer within 15 years (95% CI, 0.00%–0.32%), and their 10-year incidence of aggressive disease was low (0.25%; 95% CI, 0.00%–0.53%). Compared with white men, black men with PSA ≤ 1 ng/mL had higher 10-year rates of aggressive disease (1.6% vs. 0.4%; P < 0.01). Five-year screening intervals may be appropriate for the 45% of men with PSA ≤ 1 ng/mL. Men ages ≥65 years with PSA ≤ 0.5 ng/mL could consider stopping screening. Substantial risk disparities suggest appropriate screening intervals could depend on race/ethnicity.


  • PLCO: Evolution of an Epidemiologic Resource and Opportunities for Future Studies

    by Amanda Black, Wen-Yi Huang, Patrick Wright, Tom Riley, Jerome Mabie, Sunitha Mathew, Lawrence Ragard, Sigurd Hermansen, Kelly Yu, Paul Pinsky, et al.

    The Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO), a large-scale, multi-institutional, randomized controlled trial, was launched in 1992 to evaluate the effectiveness of screening modalities for prostate, lung, colorectal, and ovarian cancer. However, PLCO was additionally designed to serve as an epidemiologic resource and the National Cancer Institute has invested substantial resources over the years to accomplish this goal. In this report, we provide a summary of changes to PLCO’s follow-up after conclusion of the screening phase of the trial and highlight recent data and biospecimen collections, including ancillary studies, geocoding, administration of a new medication use questionnaire, consent for linkage to Medicare, and additional tissue collection that enhance the richness of the PLCO resource and provide further opportunities for scientific investigation into the prevention, early detection, etiology and treatment of cancer.


  • Open Access

    Genetic risk variants associated with in situ breast cancer

    by Daniele Campa, Myrto Barrdahl, Mia M. Gaudet, Amanda Black, Stephen J. Chanock, W. Ryan Diver, Susan M. Gapstur, Christopher Haiman, Susan Hankinson, Aditi Hazra, et al.

    Breast cancer in situ (BCIS) diagnoses, a precursor lesion for invasive breast cancer, comprise about 20 % of all breast cancers (BC) in countries with screening programs. Family history of BC is considered one of the strongest risk factors for BCIS. To evaluate the association of BC susceptibility loci with BCIS risk, we genotyped 39 single nucleotide polymorphisms (SNPs), associated with risk of invasive BC, in 1317 BCIS cases, 10,645 invasive BC cases, and 14,006 healthy controls in the National Cancer Institute’s Breast and Prostate Cancer Cohort Consortium (BPC3). Using unconditional logistic regression models adjusted for age and study, we estimated the association of SNPs with BCIS using two different comparison groups: healthy controls and invasive BC subjects to investigate whether BCIS and BC share a common genetic profile. We found that five SNPs (CDKN2BAS-rs1011970, FGFR2-rs3750817, FGFR2-rs2981582, TNRC9-rs3803662, 5p12-rs10941679) were significantly associated with BCIS risk (P value adjusted for multiple comparisons <0.0016). Comparing invasive BC and BCIS, the largest difference was for CDKN2BAS-rs1011970, which showed a positive association with BCIS (OR = 1.24, 95 % CI: 1.11–1.38, P = 1.27 x 10−4) and no association with invasive BC (OR = 1.03, 95 % CI: 0.99–1.07, P = 0.06), with a P value for case-case comparison of 0.006. Subgroup analyses investigating associations with ductal carcinoma in situ (DCIS) found similar associations, albeit less significant (OR = 1.25, 95 % CI: 1.09–1.42, P = 1.07 x 10−3). Additional risk analyses showed significant associations with invasive disease at the 0.05 level for 28 of the alleles and the OR estimates were consistent with those reported by other studies. Our study adds to the knowledge that several of the known BC susceptibility loci are risk factors for both BCIS and invasive BC, with the possible exception of rs1011970, a putatively functional SNP situated in the CDKN2BAS gene that may be a specific BCIS susceptibility locus.


  • Sex Steroid Hormone Metabolism in Relation to Risk of Aggressive Prostate Cancer

    by Amanda Black, Paul F. Pinsky, Robert L. Grubb, Roni T. Falk, Ann W. Hsing, Lisa Chu, Tamra Meyer, Timothy D. Veenstra, Xia Xu, Kai Yu, et al.

    Background: The combined action of androgens and estrogens—specifically their balance—may play a role in prostate carcinogenesis, but existing evidence is sparse and inconsistent. We investigated associations between serum sex steroid hormones, including estrogen metabolites, and risk of aggressive prostate cancer. Methods: In a case–control study nested within the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial cohort, we measured serum estrone, estradiol, and 13 estrogen metabolites, in the 2-, 4-, or 16-hydroxylation pathways, using an LC/MS-MS assay. Cases (n = 195) were non-Hispanic white men ages 55 to 70 years when diagnosed with aggressive prostate cancer (stage III or IV and/or Gleason ≥7). Controls (n = 195) were non-Hispanic white men without prostate cancer who were frequency matched to cases by age and year at blood draw, and time since baseline screen. Only men with serum testosterone and sex hormone-binding globulin measured previously were eligible. Logistic regression models were used to estimate ORs and 95% confidence intervals (95% CI). Results: Risk of aggressive prostate cancer was strongly inversely associated with estradiol:testosterone ratio (OR4th quartile vs. 1st = 0.27; 95% CI, 0.12–0.59, Ptrend = 0.003) and positively associated with 2:16α-hydroxyestrone ratio (OR4th quartile vs. 1st = 2.44; 95% CI, 1.34–4.45, Ptrend = 0.001). Individual estrogen metabolites were unrelated to risk. Conclusions: Our findings suggest that sex steroid hormones, specifically the estrogen-androgen balance, may be important in the development of aggressive prostate cancer. Impact: Improved understanding of the hormonal etiology of prostate cancer is critical for prevention and therapeutic interventions. Cancer Epidemiol Biomarkers Prev; 23(11); 2374–82. ©2014 AACR.


  • Circulating Adipokine Levels and Endometrial Cancer Risk in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial

    by Patricia Luhn, Cher M. Dallal, Jocelyn M. Weiss, Amanda Black, Wen-Yi Huang, James V. Jr Lacey, Richard B. Hayes, Frank Z. Stanczyk, Nicolas Wentzensen, Louise A. Brinton

    Adipokines are obesity-related factors produced in adipose tissue and secreted into the circulation. Several studies have shown a clear relationship for serum levels of 2 adipokines, adiponectin and leptin, with obesity in humans. There is an inverse correlation between levels of adiponectin and obesity, whereas levels of leptin appear to be positively correlated with obesity. Data from a limited number of epidemiologic studies suggest that circulating levels of adiponectin may also be associated with risk of endometrial cancer (EC); few prospective studies have examined this possible relationship. A number of case-control studies and 1 recent prospective study have suggested a positive association between leptin levels and EC. Some epidemiologic studies have shown a positive association between serum levels of visfatin, a recently discovered adipokine, in visceral fat and several cancers; however, its association with EC risk has not been evaluated. The relationship of prediagnostic serum levels of adiponectin, leptin, and visfatin with risk of EC was investigated prospectively in this case-control study, which was nested within the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. The association of circulating estradiol and body mass index (BMI) was also evaluated. A total of 78,216 postmenopausal women enrolled in the PLCO trial were randomized to either intervention (screening for incident EC, n= 167) or a matched control (usual care, n = 327). At baseline, study subjects and controls were matched for age, race, study center, study year of diagnosis, year of blood draw, time of day of blood collection, and use of menopausal hormone therapy (MHT). Serum concentrations of adiponectin, leptin, visfatin, and estradiol were categorized into tertiles. Conditional logistic regression analysis was used to estimate the associations of adiponectin, leptin, and visfatin with EC risk, adjusting for known risk factors, including BMI and plasma estradiol levels. Data for never and former MHT users were combined; results were similar when the population was restricted to never users only. There was an inverse association between elevated adiponectin levels and risk of EC (odds ratio [OR], T3 vs T1, 0.48; 95% confidence interval [CI], 0.29–0.80; P trend = 0.004), whereas higher levels of leptin were associated with increased risk (OR, T3 vs T1, 2.77; 95% CI, 1.60–4.79; P trend < 0.001). The associations remained significant after adjustment for estradiol, but not BMI. Stronger magnitudes of association with EC for adiponectin and leptin were found among women not using MHT (adiponectin [OR, T3 vs T1, 0.13; 95% CI, 05–0.35; P trend < 0.001] and leptin [OR, T3 vs T1, 9.19; 95% CI, 3.07–27.44; P trend < 0.001]). These associations remained statistically significant after adjustment for estradiol and BMI. Changes in visfatin levels were not associated with increased risk of EC. These findings suggest that, in addition to the estradiol pathway, a nonhormonal pathway involving adipokines may play an important role in endometrial carcinogenesis in postmenopausal women, especially among non-MHT users.

  • Potential effect of the risk of ovarian cancer algorithm (ROCA) on the mortality outcome of the Prostate, Lung, Colorectal and Ovarian (PLCO) trial

    by Paul F. Pinsky, Claire Zhu, Steve J. Skates, Amanda Black, Edward Partridge, Saundra S. Buys, Christine D. Berg

    Recently, the Prostate, Lung, Colorectal and Ovarian (PLCO) Trial reported no mortality benefit for annual screening with CA‐125 and transvaginal ultrasound (TVU). Currently ongoing is the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS), which utilizes the risk of ovarian cancer algorithm (ROCA), a statistical tool that considers current and past CA125 values to determine ovarian cancer risk. In contrast, PLCO used a single cutoff for CA125, based on current levels alone. We investigated whether having had used ROCA in PLCO could have, under optimal assumptions, resulted in a significant mortality benefit by applying ROCA to PLCO CA125 screening values. A best‐case scenario assumed that all cancers showing a positive screen result earlier with ROCA than under the PLCO protocol would have avoided mortality; under a stage‐shift scenario, such women were assigned survival equivalent to Stage I/II screen‐detected cases. Updated PLCO data show 132 intervention arm ovarian cancer deaths versus 119 in usual care (relative risk, RR = 1.11). Forty‐three ovarian cancer cases, 25 fatal, would have been detected earlier with ROCA, with a median (minimum) advance time for fatal cases of 344 (147) days. Best‐case and stage‐shift scenarios gave 25 and 19 deaths prevented with ROCA, for RRs of 0.90 (95% CI: 0.69–1.17) and 0.95 (95% CI: 0.74–1.23), respectively. Having utilized ROCA in PLCO would not have led to a significant mortality benefit of screening. However, ROCA could still show a significant effect in other screening trials, including UKCTOCS.


  • Open Access

    Who should be included in a clinical trial of screening for bladder cancer?

    by Andrew J. Vickers, Caroline Bennette, Adam S. Kibel, Amanda Black, Grant Izmirlian, Andrew J. Stephenson, Bernard Bochner

    BACKGROUND: Because of its relatively low incidence, bladder cancer screening might have a better ratio of benefits to harms if it is restricted to a high‐risk population. Data from the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial were used and simple decision analytic techniques were applied to compare different eligibility criteria for a screening trial.METHODS: For a variety of possible eligibility criteria, the percentage of the population aged 55 years to 74 years and classified as being at high risk for developing invasive or high‐grade carcinoma, and therefore likely to benefit from screening, was calculated. Regression models were used to calculate a risk score based on age, sex, smoking history, and family history of bladder cancer. The reduction in cases was calculated given hypothetical risk reductions associated with screening. The trade‐off between patients screened and tumors avoided was calculated as a net benefit.RESULTS: The 5‐year probability of being diagnosed with invasive bladder cancer was 0.24%. Using a risk score > 6 or > 8 as the eligibility criterion for a trial was generally superior to including all older adults. In a typical scenario, a risk score > 6 would result in approximately 25% of the population being screened to prevent 57 invasive or high‐grade bladder cancers per 100,000 population; screening the entire population would prevent only an additional 38 cases.CONCLUSIONS: Screening for bladder cancer can be optimized by restricting it to a subgroup of patients considered to be at elevated risk. Different eligibility criteria for a screening trial can be compared rationally using decision‐analytic techniques. Cancer 2013. © 2012 American Cancer Society.


  • Open Access

    Applying strategies from libertarian paternalism to decision making for prostate specific antigen (PSA) screening

    by David C Wheeler, Konrad M Szymanski, Amanda Black, David E Nelson

    Despite the recent publication of results from two randomized clinical trials, prostate specific antigen (PSA) screening for prostate cancer remains a controversial issue. There is lack of agreement across studies that PSA screening significantly reduces prostate cancer mortality. In spite of these facts, the widespread use of PSA testing in the United States leads to overdetection and overtreatment of clinically indolent prostate cancer, and its associated harms of incontinence and impotence.


  • PRE-BIOPSY PROSTATE CANCER NOMOGRAMS BASED UPON SERIAL PSA SCREENING DATA IN THE PLCO TRIAL WITH VERIFICATION BIAS CORRECTION

    by Grant Izmirlian, Robert L Grubb, Amanda Black, Philip C Prorok, Christine D Berg, E David Crawford, Gerald L Andriole, Adam S Kibel